Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 1999
Business Overview: Myriad is a genomics company focused on discovering disease-predisposing genes and developing therapeutic and diagnostic products. Its strategy relies on three commercial pillars: (1) therapeutic product development via strategic alliances and its subsidiary Myriad Pharmaceuticals; (2) marketing subscriptions to its ProNet(TM) protein interaction database; and (3) molecular diagnostic testing services (e.g., BRACAnalysis(TM) and CardiaRisk(TM)) through its subsidiary Myriad Labs.
Key Financial Metrics
| Metric | Fiscal 1999 | Fiscal 1998 |
|---|---|---|
| Total Revenues | $25,313,406 | $23,210,581 |
| Research Revenue | $20,093,057 | $20,999,598 |
| Molecular Diagnostic Revenue | $5,220,349 | $2,210,983 |
| Net Loss | ($9,995,453) | ($9,797,035) |
| Operating Loss | ($12,310,688) | ($12,990,150) |
| Cash & Cash Equivalents | $5,404,944 | $14,595,034 |
| Total Cash & Investments | $38,926,459 | $53,109,493 |
| Working Capital | $8,348,224 | $21,806,290 |
| Accumulated Deficit | ($43,939,880) | ($33,944,427) |
| Long-Term Debt | $0 | $0 |
Note: The company had no long-term notes payable as of June 30, 1999, having retired its equipment financing facility during the year.
Material Changes vs. Prior Period
- Revenue Composition: While total revenue increased by 9%, the mix shifted significantly. Research revenue declined 4.3% primarily due to the absence of $3.95 million in milestone and contract expansion payments recognized in 1998. Conversely, molecular diagnostic revenue surged 136% to $5.2 million, driven by the commercialization of BRACAnalysis(TM) and CardiaRisk(TM).
- Expenses: Research and Development (R&D) expenses increased slightly to $23.5 million due to expanded collaborations and the formation of Myriad Pharmaceuticals. Selling, General, and Administrative (SG&A) expenses decreased by $701,503 to $11.1 million, attributed to reduced legal defense costs and a stabilized sales force compared to the heavy start-up costs in 1998.
- Liquidity: Cash and cash equivalents decreased by approximately $9.2 million, and total working capital dropped by $13.5 million. This was driven by net cash used in operating activities of $14.1 million, reflecting the company's continued investment in R&D and operations exceeding cash inflows.
Guidance, Outlook, and Risks
Outlook and Management Commentary: Management expects to incur losses for at least the next several years due to the expansion of R&D programs, staffing costs, and facility growth. The company anticipates substantial future capital requirements to support clinical correlation testing, patent enforcement, and the commercialization of gene discoveries. Management believes existing capital resources are adequate for at least the next two years but intends to raise funds when conditions are favorable.
Strategic Milestones:
- Entered a five-year, up to $51 million collaboration with Schering AG to utilize ProNet(TM).
- Secured a $15 million collaboration with Monsanto for drug discovery.
- Extended the strategic alliance with Bayer, potentially adding up to $12 million in funding and milestone payments.
- Subsequent Event (July 1999): Entered a $33.5 million collaboration with Novartis Agricultural Discovery Institute.
Risks and Contingencies:
- Profitability: The company has been unprofitable since inception with an accumulated deficit of nearly $44 million.
- Regulatory: Molecular diagnostics and therapeutics require FDA and state-level approvals (e.g., CLIA certification). Changes in regulations could materially affect operations.
- Competition: Intense competition exists in gene discovery and therapeutic development from major pharmaceutical companies and academic institutions.
- Year 2000 Issue: While Phase I review suggests no material effect, Phase II testing is ongoing. Failure to resolve Y2K issues could disrupt operations, billing, and R&D.
- Reimbursement: Commercial success of diagnostic tests depends on third-party reimbursement and market acceptance.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $14.1 million operating cash outflow against the $38.9 million total cash and investment balance.
- Revenue Recognition: Confirm the timing of milestone payments from collaborators (Bayer, Schering, Novartis) as these significantly impact reported revenue volatility.
- Diagnostic Growth: Assess the 136% growth in molecular diagnostic revenue and the associated receivables (which increased to 20-25% of diagnostic revenue) to ensure collection trends remain healthy.
- Collaboration Dependencies: Review the terms of the top four collaborators, who accounted for the vast majority of research revenue, to understand concentration risk.
- Intellectual Property: Evaluate the status of patent applications for key genes (BRCA1, BRCA2, CHD1, MMAC1) and potential litigation risks.